concomit
express
activ
form
akt
ra
mous
liver
aktra
lead
rapid
tumor
develop
via
strong
activ
pathway
function
via
regul
cascad
cascad
contribut
hepatocarcinogenesi
remain
unknown
show
inhibit
pathway
via
rapamycin
effect
suppress
wherea
blockad
cascad
unphosphorylat
form
significantli
delay
aktra
induc
hepatocarcinogenesi
combin
treatment
rapamycin
complet
inhibit
aktra
hepatocarcinogenesi
strong
antineoplast
effect
success
recapitul
ablat
raptor
major
subunit
aktrasoverexpress
liver
furthermor
demonstr
overexpress
protooncogen
whose
activ
specif
inhibit
result
hcc
develop
cooper
activ
ra
mechanist
identifi
axi
mitochondri
biogenesi
pathway
target
cascad
aktra
liver
well
human
hcc
cell
line
tissu
conclusionscomplet
inhibit
requir
suppress
liver
cancer
develop
induc
akt
ra
protooncogen
mice
effector
play
distinct
role
necessari
aktra
hepatocarcinogenesi
hepatocellular
carcinoma
hcc
common
type
liver
cancer
fourth
lead
caus
cancer
death
worldwid
treatment
option
hcc
limit
gener
ineffect
small
percentag
hcc
diagnos
earli
stage
amen
potenti
cur
treatment
surgic
resect
liver
transplant
radiofrequ
ablat
approv
drug
treatment
advanc
hcc
sorafenib
multikinas
inhibitor
whose
overal
efficaci
term
patient
surviv
extens
howev
rather
limit
thu
develop
novel
therapeut
strategi
advanc
hcc
mandatori
purpos
deeper
knowledg
molecular
mechan
underli
hepatocarcinogenesi
necessari
one
frequent
activ
pathway
hcc
cascad
implic
tumor
initi
progress
metastasi
follow
phosphoinositid
activ
receptor
tyrosin
kinas
g
protein
coupl
receptor
akt
vakt
murin
thymoma
viral
oncogen
homolog
recruit
membran
phosphoryl
mous
hepatocyt
overexpress
activ
form
akt
myrakt
induc
lipogenesi
hepatocyt
prolifer
eventu
lead
hcc
develop
within
six
month
akt
exert
mani
effect
target
cell
key
downstream
effector
mtor
complex
axi
also
frequent
activ
human
hcc
use
mice
liverspecif
delet
raptor
regulatori
associ
protein
essenti
compon
recent
studi
show
control
ketogenesi
mice
respons
fast
modul
age
moreov
chronic
activ
mice
liverspecif
delet
lead
hepatocarcinogenesi
major
regul
downstream
neg
regul
key
ratelimit
initi
factor
capdepend
translat
phosphoryl
lead
dissoci
allow
translat
initi
complex
format
end
mrna
mediat
translat
control
shown
key
downstream
signal
aktinduc
lymphomagenesi
vivo
critic
mediat
cell
prolifer
moreov
found
major
effector
oncogen
activ
akt
erk
signal
pathway
tumor
cell
line
xenograft
model
anoth
downstream
effector
phosphoryl
activ
turn
regul
ribosom
protein
well
regul
translat
initi
ablat
mous
hepatocyt
inhibit
cell
prolifer
partial
hepatectomi
also
five
phosphorylat
serin
residu
substitut
unphosphorylat
alanin
knockin
p
mice
display
cell
growth
defect
use
p
mice
previou
studi
show
loss
phosphoryl
dispens
aktmedi
lymphomagenesi
rapamycin
alloster
partial
inhibitor
analogu
rapalog
test
clinic
anticanc
agent
multipl
tumor
type
howev
rapalog
show
modest
clinic
efficaci
presum
due
capac
suppress
phosphoryl
concomit
activ
aktmtor
rasmapk
cascad
frequent
observ
human
hcc
elucid
molecular
biochem
crosstalk
two
pathway
gener
mous
model
liver
cancer
character
coexpress
activ
form
akt
nra
current
studi
use
genet
pharmacolog
approach
systemat
investig
requir
two
main
downstream
effector
aktrasinduc
hepatocarcinogenesi
vivo
data
demonstr
complet
inhibit
requir
suppress
hepatocarcinogenesi
driven
nra
akt
oncogen
mice
wildtyp
fvbn
mice
obtain
charl
river
wilmington
raptor
fl
mice
purchas
jackson
laboratori
stock
intercross
gener
raptor
flfl
mice
hydrodynam
inject
perform
describ
previous
delet
raptor
coexpress
akt
andor
ra
inject
high
dose
low
dose
akt
andor
ra
ensur
oncogen
express
cell
also
express
cre
led
delet
target
flox
allel
inject
ha
tag
akt
mice
mice
cremedi
excis
flox
termin
sequenc
lead
constitut
eyfp
express
subsequ
doubl
immunofluoresc
stain
show
ha
posit
akt
express
cell
also
eyfp
posit
supplementari
fig
support
notion
abl
simultan
delet
target
flox
allel
express
oncogen
set
hepatocyt
rapamycin
vehicl
intraperiton
administ
week
immedi
hydrodynam
inject
block
cascad
high
dose
low
dose
akt
andor
ra
inject
gener
mice
alon
hydrodynam
inject
fvbn
mice
wildtyp
inject
mice
inject
empti
plasmid
use
control
sinc
differ
paramet
analyz
two
control
group
detect
data
merg
mice
hous
fed
monitor
accord
protocol
approv
committe
anim
research
univers
california
san
francisco
previous
show
rapamycin
administr
week
suppress
activ
aktra
mice
thoroughli
investig
contribut
along
aktra
induc
hepatocarcinogenesi
rapamycin
administ
daili
week
aktra
mice
immedi
hydrodynam
inject
supplementari
fig
accord
previou
find
rapamycin
treatment
effici
block
express
liver
aktra
mice
without
affect
level
fig
suppress
parallel
prevent
hepatocarcinogenesi
rapamycin
treat
aktra
mice
inde
none
rapamycin
treat
aktra
mice
develop
palpabl
liver
tumor
week
post
inject
wherea
vehicl
treat
aktra
mice
develop
lethal
burden
liver
tumor
fig
b
histolog
liver
lesion
rapamycin
treat
aktra
mice
consist
small
cluster
lipidrich
preneoplast
hepatocyt
fig
alter
cell
show
stabl
integr
inject
construct
fig
overexpress
pakt
variabl
express
posit
cell
shown
pmtor
fig
equival
scatter
cluster
preneoplast
hepatocyt
tumor
lesion
detect
aktra
mice
rapamycin
administ
week
postinject
data
shown
suggest
continu
rapamycin
treatment
might
imped
appear
frankli
malign
tumor
aktra
liver
altogeth
find
demonstr
critic
downstream
effector
requir
aktrasdriven
hepatocarcinogenesi
investig
contribut
axi
aktra
induc
hepatocarcinogenesi
overexpress
empti
vector
control
wildtyp
mutant
form
phosphoryl
inactiv
along
akt
nra
mous
liver
via
hydrodynam
inject
supplementari
fig
previou
find
show
abl
effici
block
mediat
capdepend
translat
initi
downstream
accordingli
found
overexpress
rapamycin
treatment
inhibit
capdepend
translat
aktra
mous
liver
tumor
cell
line
supplementari
fig
cell
line
use
sinc
accur
recapitul
molecular
mechan
respons
aktra
induc
hepatocarcinogenesi
seven
week
hydrodynam
inject
none
mice
develop
palpabl
liver
mass
fig
contrast
mice
aktra
cohort
develop
lethal
burden
liver
tumor
supplementari
fig
grossli
small
nodul
could
observ
liver
mice
wherea
numer
larg
nodul
equal
develop
liver
mice
week
post
inject
fig
supplementari
fig
histolog
cluster
lipidrich
preneoplast
hepatocyt
occupi
liver
parenchyma
character
mice
time
point
fig
hatag
detect
clearcel
preneoplast
hepatocyt
demonstr
stabl
transfect
akt
hatag
cell
fig
frankli
malign
lesion
detect
next
three
mice
age
determin
whether
liver
tumor
could
eventu
develop
mice
palpabl
liver
mass
appreci
week
post
inject
fig
liver
mice
occupi
mainli
premalign
hca
lesion
small
hcc
icc
lesion
fig
tumor
prolifer
indic
stain
fig
serial
section
liver
tumor
demonstr
express
inject
construct
name
akt
hatag
indic
tumor
develop
presenc
ectop
express
fig
moreov
elev
immunoreact
pakt
pmtor
detect
fig
summari
data
indic
mediat
cap
depend
translat
initi
critic
role
along
aktra
hepatocarcinogenesi
inhibit
significantli
delay
complet
prevent
liver
tumor
develop
aktra
mice
although
block
result
strike
reduct
preneoplast
lesion
andor
remark
delay
tumor
develop
preneoplast
andor
neoplast
lesion
still
observ
follow
two
distinct
treatment
thu
investig
whether
complet
suppress
concomit
inhibit
could
complet
abolish
aktra
hepatocarcinogenesi
purpos
mice
coinject
akt
ra
treat
rapamycin
vehicl
week
supplementari
fig
macroscop
tumor
nodul
could
detect
liver
surfac
mice
fig
histolog
examin
reveal
liver
tissu
aktra
mice
nearli
normal
isol
never
cluster
cell
show
lipidrich
featur
aktra
preneoplast
cell
fig
alter
clearcel
hepatocyt
haposit
demonstr
stabl
transfect
inject
akt
fig
note
lipidrich
cell
mice
show
scarc
activ
akt
erk
mtor
protein
immunohistochemistri
fig
impli
suppress
cascad
residu
preneoplast
cell
contrast
akt
erk
protein
still
activ
small
cluster
preneoplast
cell
rapamycin
treat
aktra
mice
aktrasrapa
fig
preneoplast
lesion
inject
mice
shown
addit
differ
prolif
activ
detect
liver
compar
liver
mice
inject
empti
vector
vs
respect
p
per
group
valid
find
complet
inhibit
requir
fulli
suppress
aktra
induc
liver
tumor
format
vivo
util
raptor
flfl
mice
coinject
akt
ra
togeth
empti
vector
aktrascr
raptor
flfl
mice
supplementari
fig
found
raptor
flfl
mice
inject
vector
develop
lethal
burden
liver
tumor
within
week
post
inject
strike
contrast
raptor
flfl
mice
inject
aktrascr
develop
preneoplast
neoplast
lesion
fig
histolog
liver
tumor
inject
raptor
flfl
mice
undistinguish
develop
wild
type
mice
coexpress
akt
ra
preneoplast
lesion
tumor
occupi
liver
parenchyma
tumor
cell
highli
prolif
fig
contrast
liver
tissu
aktrascr
inject
raptor
flfl
mice
complet
normal
sign
preneoplast
neoplast
lesion
fig
upper
panel
thorough
histolog
investig
liver
abl
detect
singl
haposit
clearcel
hepatocyt
fig
lower
panel
notic
observ
effect
due
ablat
raptor
cre
result
nonspecif
effect
cre
aktrascr
inject
wildtyp
mice
lethal
burden
liver
tumor
develop
mice
week
post
inject
similar
observ
aktra
inject
mice
data
shown
determin
whether
liver
tumor
might
eventu
develop
long
term
aktrascr
inject
raptor
flfl
mice
age
week
post
inject
none
latter
mice
develop
preneoplast
neoplast
lesion
fig
data
shown
altogeth
studi
demonstr
aktra
driven
hepatocarcinogenesi
depend
function
vivo
complet
inhibit
requir
fulli
suppress
hepatocarcinogenesi
mous
model
next
investig
cellular
mechan
respons
inhibit
aktrasdriven
hepatocarcinogenesi
follow
suppress
andor
cascad
purpos
compar
prolif
apoptot
rate
preneoplast
lesion
isol
preneoplast
cell
variou
model
time
point
week
postinject
supplementari
fig
signific
differ
prolifer
detect
compar
wildtyp
liver
preneoplast
lesion
aktrascr
inject
raptor
flfl
mice
wherea
slightli
higher
prolif
activ
detect
aktrasrapa
mice
progress
increas
prolifer
occur
preneoplast
lesion
mice
highest
prolifer
index
observ
aktra
mice
concern
apoptosi
signific
differ
detect
cell
death
rate
among
variou
mous
group
supplementari
fig
result
suggest
suppress
andor
cascad
mainli
associ
prolifer
restraint
aktra
mice
elucid
molecular
mechan
pathway
aktra
induc
hepatocarcinogenesi
assess
effect
inhibit
axi
aktra
liver
molecular
level
immunoblot
wildtyp
aktra
aktra
rapa
liver
tissu
level
phosphorylatedactiv
akt
drastic
reduc
two
experiment
group
compar
untreat
aktra
mice
fig
level
phosphorylatedinactiv
unmodifi
follow
rapamycin
treatment
wherea
strong
induct
detect
aktra
mice
mechan
increas
clear
like
due
either
increas
phosphoryl
endogen
protein
crossreact
antibodi
inject
construct
level
unchang
two
treat
group
wherea
activatedphosphoryl
eukaryot
initi
factor
bind
allow
earli
step
protein
translat
complet
abolish
mice
fig
well
character
exert
activ
via
regul
cell
metabol
next
investig
effect
treatment
metabol
pathway
modul
mtor
involv
de
novo
lipogenesi
glycolysi
equal
downregul
two
treat
group
contrast
induc
glycolysi
ldhac
downstream
effector
downregul
almost
exclus
mice
importantli
ldhac
downregul
occur
independ
cmyc
sinc
latter
mainli
downregul
follow
rapamycin
administr
fig
furthermor
although
demonstr
inhibit
endoplasm
reticulum
er
stress
pathway
level
er
stress
surrog
marker
includ
chop
bip
phosphorylatedactiv
perk
induc
mice
fig
sinc
recent
found
protein
neg
regul
mitochondri
activ
biogenesi
test
level
master
regul
mitochondri
biogenesi
mitochondri
transcript
factor
tfam
note
tfam
downregul
mice
fig
addit
establish
target
axi
name
cyclin
downregul
aktra
mice
final
import
aktrasinduc
hepatocarcinogenesi
assess
sirnamedi
silenc
aktra
cell
line
supplementari
fig
inhibit
result
decreas
prolifer
induct
apoptosi
aktra
cell
compar
control
cell
supplementari
fig
c
molecular
level
aktra
cell
deplet
show
relev
chang
level
protein
involv
er
stress
bip
pperk
glycolysi
ldhac
hexokinas
ii
hxii
liver
phosphofructokinas
pfkl
aldolas
aldoa
supplementari
fig
present
data
indic
cascad
control
differ
target
aktra
driven
hepatocarcinogenesi
next
sought
determin
whether
whose
activ
inhibit
oncogen
mous
liver
purpos
gene
tag
ha
hydrodynam
transfect
wildtyp
mice
neither
preneoplast
neoplast
liver
lesion
develop
mice
week
post
inject
supplementari
fig
although
hepatocyt
show
integr
construct
supplementari
fig
indic
alon
suffic
malignantli
transform
hepatocyt
nevertheless
significantli
higher
hepatocyt
prolifer
rate
inject
mice
mice
inject
empti
plasmid
detect
vs
respect
n
per
group
p
molecular
level
liver
show
strike
coloc
ha
confirm
latter
axi
modul
cascad
mous
liver
immunoreact
perk
pakt
pmtor
detect
liver
supplementari
fig
next
assess
whether
cooper
rasmapk
pathway
cascad
affect
rapamycin
treatment
aktra
mice
previou
studi
show
overexpress
nra
alon
via
hydrodynam
inject
lead
liver
morpholog
alter
week
postinject
similarli
coexpress
nra
result
hepat
histolog
alter
week
post
inject
data
shown
howev
multipl
hepatocellular
tumor
consist
hca
hcc
detect
mice
week
post
inject
fig
b
mice
hepatocyt
mice
express
protein
also
exhibit
strong
immunolabel
fig
neg
pakt
pmtor
stain
fig
note
strong
perk
stain
detect
preneoplast
neoplast
lesion
mice
indic
success
express
deliv
ra
plasmid
fig
altogeth
present
data
indic
oncogen
per
se
mous
liver
act
synergist
nra
induc
hepat
tumor
develop
independ
cascad
due
novel
find
link
aktra
mice
assess
whether
appli
human
hcc
purpos
overexpress
either
hlf
human
hcc
cell
line
notabl
overexpress
lower
extent
led
downregul
target
hlf
cell
supplementari
fig
consist
vivo
data
rapamycin
treatment
effect
express
hlf
cell
supplementari
fig
addit
overexpress
mostli
rapamycin
treatment
result
downregul
activatedphosphoryl
tfam
protein
accord
mous
data
supplementari
fig
fig
furthermor
concomit
rapamycin
administr
transient
transfect
result
much
pronounc
growth
restraint
either
treatment
alon
hlf
cell
supplementari
fig
confirm
target
cascad
differ
liver
cancer
final
analyz
collect
human
hcc
specimen
immunohistochemistri
stronger
immunoreact
compar
nontumor
surround
counterpart
detect
hcc
respect
note
hcc
display
increas
immunoreact
concomitantli
show
upregul
fig
associ
stain
pattern
clinicopatholog
featur
patient
includ
etiolog
presenc
cirrhosi
level
tumor
grade
surviv
length
detect
data
shown
altogeth
present
data
indic
control
express
downstream
effector
human
hcc
master
regul
plethora
process
influenc
cell
prolifer
surviv
function
mainli
via
regul
cascad
two
cascad
best
character
activ
axi
trigger
cell
growth
prolifer
promot
protein
lipid
synthesi
gene
transcript
cell
metabol
current
previou
studi
demonstr
rapamycin
specif
block
without
affect
cascad
rapamycin
treatment
effici
prevent
aktra
driven
liver
tumor
develop
suggest
critic
downstream
effector
hand
littl
instead
known
cascad
particular
role
pathway
cancer
remain
poorli
understood
found
main
effector
akt
erk
signal
pathway
vitro
vivo
model
consequ
surpris
elev
level
describ
multipl
tumor
type
includ
lung
bladder
colon
breast
prostat
cervix
ovari
thyroid
neoplasm
regard
hcc
recent
investig
show
increas
express
tumor
sampl
signific
associ
level
tumor
recurr
present
studi
dissect
first
time
critic
function
axi
context
activ
aktmtor
rasmapk
cascad
along
hepatocarcinogenesi
data
demonstr
block
activ
via
unphosphorylat
form
significantli
delay
liver
tumor
develop
progress
induc
akt
ra
oncogen
inde
liver
tumor
observ
long
latenc
consist
mainli
hca
small
hcc
icc
mice
nevertheless
despit
strong
tumor
suppressor
activ
overexpress
unabl
complet
inhibit
liver
tumor
develop
find
suggest
aktra
driven
hepatocarcinogenesi
abl
least
part
overcom
defici
relat
biolog
effect
cellular
level
found
inhibit
andor
axe
mainli
affect
prolifer
rather
apoptosi
aktra
preneoplast
cell
suggest
direct
correl
prolif
activ
preneoplast
cell
propens
tumor
format
mous
model
data
agreement
previou
studi
show
everolimu
rapalog
effici
inhibit
chronic
injuri
induc
hepatocyt
prolifer
dnadamag
induc
liver
tumor
develop
mice
altogeth
studi
support
import
role
regul
hepatocyt
prolifer
suggest
suppress
andor
axe
may
help
delay
hcc
develop
patient
risk
inhibit
tumor
recurr
anoth
major
find
present
studi
identif
novel
downstream
target
axi
liver
despit
assumpt
regul
translat
global
level
mount
evid
suggest
contribut
tumorigenesi
regul
small
set
protein
cyclin
vegf
cmyc
show
pathway
major
biochem
event
downstream
mous
human
hepatocarcinogenesi
endoplasm
reticulum
er
udpas
togeth
regul
futil
cycl
convert
atp
amp
lead
compensatori
increas
aerob
glycolysi
thu
might
play
major
role
promot
atp
consumpt
satisfi
energet
biosynthet
requir
aktra
cell
addit
found
favour
protein
glycosyl
refold
protect
tumor
cell
protein
overload
induc
er
stress
surprisingli
detect
sign
er
stress
induct
follow
inactiv
overexpress
mice
aktra
cell
similarli
er
stress
glycolysi
protein
affect
deplet
aktra
cell
find
suggest
might
play
distinct
role
contextor
celltyp
depend
although
addit
studi
need
identifi
target
liver
cancer
confirm
strong
connect
axe
human
hcc
specimen
hlf
cell
substanti
import
link
two
cascad
liver
cancer
interestingli
found
control
also
final
step
anaerob
glycolysi
sinc
overexpress
suppress
ldhac
express
much
effici
rapamycin
aktra
mice
furthermor
inactiv
result
downregul
tfam
transcript
factor
accord
recent
find
axi
regul
mitochondri
activ
biogenesi
base
bodi
data
tempt
specul
axi
might
central
player
modul
aerob
anaerob
glycolysi
well
mitochondri
depend
metabol
anoth
major
find
present
studi
resid
evalu
oncogen
potenti
mous
liver
show
alon
abl
promot
malign
transform
murin
hepatocyt
least
experiment
condit
nevertheless
found
cooper
activ
nra
whose
overexpress
per
se
also
unabl
drive
hepatocarcinogenesi
induc
liver
tumor
develop
mous
intrigu
note
rasmapk
cascad
inhibit
rapamycin
aktra
mice
also
hepatocellular
tumor
eventu
develop
mice
display
activ
cascad
thu
identifi
crosstalk
rasmapk
axe
suffici
drive
hepatocarcinogenesi
independ
pathway
rapamycin
rapalog
everilomu
test
clinic
hcc
treatment
prevent
howev
recent
report
everolimu
fail
phase
iii
trial
treatment
advanc
hcc
http
suggest
partial
inhibit
cascad
limit
therapeut
efficaci
treatment
liver
cancer
current
data
strongli
support
use
drug
effici
inhibit
cascad
importantli
inhibit
via
compound
isol
high
throughput
screen
molecul
inhibit
interact
shown
encourag
antineoplast
effect
combinatori
administr
similar
drug
rapamycin
might
repres
innov
approach
treatment
cancer
elev
activ
refer
web
version
pubm
central
supplementari
materi
repres
immunoblot
wildtyp
wt
aktra
ar
aktrasrapa
ar
rapa
liver
tissu
five
sampl
per
group
use
arrow
left
right
side
blot
indic
correct
band
protein
dpi
control
express
target
human
hepatocellular
carcinoma
hcc
concomit
induct
coloc
hcc
upper
panel
magnif
low
level
anoth
hcc
lower
panel
magnif
dpi
